2
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Other hematologic neoplasm
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
186
HER2-positive Breast Cancer
18
Neoplasms
13
Neoplasm Metastasis
11
Prostatic Neoplasms
7
Ovarian Neoplasms
7
Stomach Neoplasms
6
Carcinoma, Non-Small-Cell Lung
6
Pancreatic Neoplasms
5
Inflammatory Breast Neoplasms
5
Colonic Neoplasms
5
Brain Neoplasms
5
Triple Negative Breast Neoplasms
4
Multiple Myeloma
4
Hematologic Neoplasms
4
Endometrial Neoplasms
4
Colorectal Neoplasms
4
Urinary Bladder Neoplasms
3
Solid Tumor
3
Rectal Neoplasms
3
Pathologic Complete Response
3
Lymphoma, Non-Hodgkin
3
Lung Neoplasms
3
HER2-positive Early Breast Cancer
3
Esophageal Neoplasms
3
Breast Neoplasms, Male
3
Biliary Tract Neoplasms
3
Anatomic Stage I Breast Cancer AJCC v8
3
Salivary Gland Neoplasms
2
Locally Advanced Breast Cancer
2
Interventions
pembrolizumab
24
Nivolumab
23
aldesleukin
21
Cyclophosphamide
20
Ipilimumab
17
Interleukin-2
17
fludarabine
15
fludarabine phosphate
14
cemiplimab
12
Radiotherapy
7
Fluorouracil
7
Biopsy
7
dabrafenib
6
Surveys and Questionnaires
6
Dacarbazine
6
trametinib
5
binimetinib
5
Vemurafenib
5
Temozolomide
5
Surgical Procedures, Operative
5
Sirolimus
5
Radiation
5
Blood Specimen Collection
5
Aminolevulinic Acid
5
sonidegib
4
encorafenib
4
Photochemotherapy
4
Mohs Surgery
4
HhAntag691
4
Educational Status
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Skin Neoplasms
×
pertuzumab
×
Clear all
NCT05786716
2025-12-02
DETERMINE
Cancer Research UK
Phase 2/3
Recruiting
30 enrolled